Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy

Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of anti-FXa activity with andexanet were assessed in patients from the ANNEXA-4 study (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effe...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Stroke
Auteurs principaux: Demchuk, Andrew M., Yue, Patrick, Zotova, Elena, Nakamya, Juliet, Xu, Lizhen, Milling, Truman J., Ohara, Tomoyuki, Goldstein, Joshua N., Middeldorp, Saskia, Verhamme, Peter, Lopez-Sendon, Jose Luis, Conley, Pamela B., Curnutte, John T., Eikelboom, John W., Crowther, Mark, Connolly, Stuart J.
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2021
Sujets:
Original Contributions
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8140631/
https://ncbi.nlm.nih.gov/pubmed/33966491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.120.030565
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires